| Dr Amit Mehta, MD | |
|
955 Bellefonte Ave, Lock Haven, PA 17745-3033 | |
| (570) 748-7714 | |
| (570) 893-6325 |
| Full Name | Dr Amit Mehta |
|---|---|
| Gender | Male |
| Speciality | Family Practice |
| Experience | 24 Years |
| Location | 955 Bellefonte Ave, Lock Haven, Pennsylvania |
| Accepts Medicare Assignments | Yes. He accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
| Identifier | Type | State | Issuer |
|---|---|---|---|
| 1205159985 | NPI | - | NPPES |
| Taxonomy | Type | License (State) | Status |
|---|---|---|---|
| 207Q00000X | Family Medicine | MD438621 (Pennsylvania) | Primary |
| Facility Name | Location | Facility Type |
|---|---|---|
| Geisinger Medical Center | Danville, PA | Hospital |
| Geisinger Jersey Shore Hospital | Jersey shore, PA | Hospital |
| Geisinger-lewistown Hospital | Lewistown, PA | Hospital |
| Williamsport Regional Medical Center | Williamsport, PA | Hospital |
| Mount Nittany Medical Center | State college, PA | Hospital |
| Group Practice Name | Group PECOS PAC ID | No. of Members |
|---|---|---|
| Geisinger-hm Joint Venture Llc | 1355676370 | 306 |
| Geisinger Clinic | 5395657001 | 2866 |
News Archive
NeuroMetrix, Inc., a science-based health care company transforming patient care through neurotechnology, today reported business and financial highlights for the quarter and year ended December 31, 2010.
A new substance class for the treatment of multiple sclerosis and other neurodegenerative diseases now promises increased efficacy paired with fewer side effects. To achieve this, a team of scientists under the leadership of Prof. Gunter Fischer and Dr. Frank Striggow have combined two already approved pharmaceutical substances with each other using a chemical linker structure.
Actavis plc today reported net revenue increased 40 percent to $2.66 billion for the first quarter ended March 31, 2014, compared to $1.90 billion in the first quarter 2013.
Celsis International, the global leader in rapid microbial detection, announced it has recently updated its Drug Master Files with the U.S. Food & Drug Administration (FDA) to include information on testing both non-sterile and sterile raw materials, in-process solutions and finished goods on the Celsis system.
The Muscular Dystrophy Association (MDA), headquartered in Tucson, Ariz., and Friends of FSH Research (FFSHR), based in Kirkland, Wash., has jointly awarded a two-year, $200,000 grant to Dr. Joel Chamberlain, a research assistant professor of medical genetics at the University of Washington. The grant, equally funded by the two organizations, will enable the laboratory led by Dr. Chamberlain to study RNA interference as an investigative and therapeutic tool for facioscapulohumeral muscular dystrophy.
› Verified 4 days ago
| Entity Name | Geisinger Clinic |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1366493868 PECOS PAC ID: 5395657001 Enrollment ID: O20040130000518 |
News Archive
NeuroMetrix, Inc., a science-based health care company transforming patient care through neurotechnology, today reported business and financial highlights for the quarter and year ended December 31, 2010.
A new substance class for the treatment of multiple sclerosis and other neurodegenerative diseases now promises increased efficacy paired with fewer side effects. To achieve this, a team of scientists under the leadership of Prof. Gunter Fischer and Dr. Frank Striggow have combined two already approved pharmaceutical substances with each other using a chemical linker structure.
Actavis plc today reported net revenue increased 40 percent to $2.66 billion for the first quarter ended March 31, 2014, compared to $1.90 billion in the first quarter 2013.
Celsis International, the global leader in rapid microbial detection, announced it has recently updated its Drug Master Files with the U.S. Food & Drug Administration (FDA) to include information on testing both non-sterile and sterile raw materials, in-process solutions and finished goods on the Celsis system.
The Muscular Dystrophy Association (MDA), headquartered in Tucson, Ariz., and Friends of FSH Research (FFSHR), based in Kirkland, Wash., has jointly awarded a two-year, $200,000 grant to Dr. Joel Chamberlain, a research assistant professor of medical genetics at the University of Washington. The grant, equally funded by the two organizations, will enable the laboratory led by Dr. Chamberlain to study RNA interference as an investigative and therapeutic tool for facioscapulohumeral muscular dystrophy.
› Verified 4 days ago
| Entity Name | Geisinger-hm Joint Venture Llc |
|---|---|
| Entity Type | Part B Supplier - Clinic/group Practice |
| Entity Identifiers | NPI Number: 1144876137 PECOS PAC ID: 1355676370 Enrollment ID: O20190826000803 |
News Archive
NeuroMetrix, Inc., a science-based health care company transforming patient care through neurotechnology, today reported business and financial highlights for the quarter and year ended December 31, 2010.
A new substance class for the treatment of multiple sclerosis and other neurodegenerative diseases now promises increased efficacy paired with fewer side effects. To achieve this, a team of scientists under the leadership of Prof. Gunter Fischer and Dr. Frank Striggow have combined two already approved pharmaceutical substances with each other using a chemical linker structure.
Actavis plc today reported net revenue increased 40 percent to $2.66 billion for the first quarter ended March 31, 2014, compared to $1.90 billion in the first quarter 2013.
Celsis International, the global leader in rapid microbial detection, announced it has recently updated its Drug Master Files with the U.S. Food & Drug Administration (FDA) to include information on testing both non-sterile and sterile raw materials, in-process solutions and finished goods on the Celsis system.
The Muscular Dystrophy Association (MDA), headquartered in Tucson, Ariz., and Friends of FSH Research (FFSHR), based in Kirkland, Wash., has jointly awarded a two-year, $200,000 grant to Dr. Joel Chamberlain, a research assistant professor of medical genetics at the University of Washington. The grant, equally funded by the two organizations, will enable the laboratory led by Dr. Chamberlain to study RNA interference as an investigative and therapeutic tool for facioscapulohumeral muscular dystrophy.
› Verified 4 days ago
| Mailing Address | Practice Location Address |
|---|---|
| Dr Amit Mehta, MD 100 N Academy Ave, Credentials Dept, Danville, PA 17822-4903 Ph: (570) 271-6144 | Dr Amit Mehta, MD 955 Bellefonte Ave, Lock Haven, PA 17745-3033 Ph: (570) 748-7714 |
News Archive
NeuroMetrix, Inc., a science-based health care company transforming patient care through neurotechnology, today reported business and financial highlights for the quarter and year ended December 31, 2010.
A new substance class for the treatment of multiple sclerosis and other neurodegenerative diseases now promises increased efficacy paired with fewer side effects. To achieve this, a team of scientists under the leadership of Prof. Gunter Fischer and Dr. Frank Striggow have combined two already approved pharmaceutical substances with each other using a chemical linker structure.
Actavis plc today reported net revenue increased 40 percent to $2.66 billion for the first quarter ended March 31, 2014, compared to $1.90 billion in the first quarter 2013.
Celsis International, the global leader in rapid microbial detection, announced it has recently updated its Drug Master Files with the U.S. Food & Drug Administration (FDA) to include information on testing both non-sterile and sterile raw materials, in-process solutions and finished goods on the Celsis system.
The Muscular Dystrophy Association (MDA), headquartered in Tucson, Ariz., and Friends of FSH Research (FFSHR), based in Kirkland, Wash., has jointly awarded a two-year, $200,000 grant to Dr. Joel Chamberlain, a research assistant professor of medical genetics at the University of Washington. The grant, equally funded by the two organizations, will enable the laboratory led by Dr. Chamberlain to study RNA interference as an investigative and therapeutic tool for facioscapulohumeral muscular dystrophy.
› Verified 4 days ago
David Luo, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 1 Outlet Ln Ste 400, Suite 400, Lock Haven, PA 17745 Phone: 570-769-1300 | |
Dr. Mary Elizabeth Piergallini, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 401 High St, Lock Haven, PA 17745 Phone: 570-747-7400 Fax: 570-748-8004 | |
Sarah Mcelroy, Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 610 High St, Lock Haven, PA 17745 Phone: 570-748-1260 | |
Shannon Seeland, MD Family Medicine Medicare: Medicare Enrolled Practice Location: 68 Spring St, Lock Haven, PA 17745 Phone: 800-230-4565 Fax: 570-893-6325 | |
Dr. Boris Gabinskiy, M.D. Family Medicine Medicare: Medicare Enrolled Practice Location: 955 Bellefonte Ave, Lock Haven, PA 17745 Phone: 570-748-7714 Fax: 570-893-6325 | |
Dr. Laura May Smith, M.D. Family Medicine Medicare: Accepting Medicare Assignments Practice Location: 610 High St, Lock Haven, PA 17745 Phone: 570-748-1260 Fax: 570-748-1261 |